We are live on ! Find out more
SC

Sophrosyne Capital Portfolio holdings

AUM $11.5M
1-Year Est. Return 17.82%
This Fund
S&P 500
This Quarter Est. Return
+4.25%
1 Year Est. Return
+17.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$13.4M
AUM Growth
-$44.9M
Cap. Flow
-$45.1M
Cap. Flow %
-337.36%
Top 10 Hldgs %
98.59%
Holding
35
New
1
Increased
–
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
GMO
General Moly, Inc.
GMO
+$11.4K

Top Sells

Rank Stock Value
1
IRMD icon
iRadimed
IRMD
+$4.94M
2
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$4.51M
3
MSTR icon
Strategy Inc
MSTR
+$4.16M
4
BEAT
BioTelemetry, Inc.
BEAT
+$3.65M
5
PKT
PROCERA NETWORKS INC NEW COM STK (DE)
PKT
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 48.11%
2 Utilities 29.4%
3 Communication Services 8.27%
4 Financials 7.81%
5 Miscellaneous 3.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAT
1
DELISTED
BioTelemetry, Inc.
BEAT
$4.08M 30.55%
432,853
-394,451
-48% -$3.65M
PCYO icon
2
Pure Cycle
PCYO
$275M
$3.05M 22.83%
587,026
-44,300
-7% -$230K
IRMD icon
3
iRadimed
IRMD
$1.11B
$1.6M 11.98%
68,751
-270,407
-80% -$4.94M
MEET
4
DELISTED
The Meet Group, Inc. Common Stock
MEET
$1.1M 8.27%
650,000
-854,032
-57% -$1.4M
BFYT
5
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$1.04M 7.81%
209,925
-272,995
-57% -$1.72M
CDZI icon
6
Cadiz
CDZI
$334M
$878K 6.57%
101,189
-137,667
-58% -$1.2M
AXGN icon
7
Axogen
AXGN
$2.78B
$745K 5.58%
237,266
-252,463
-52% -$815K
ENVI
8
DELISTED
ENVIVIO INC COM STK (DE)
ENVI
$446K 3.34%
234,852
-290,722
-55% -$523K
AVAV icon
9
AeroVironment
AVAV
$7.74B
$156K 1.17%
6,000
-42,300
-88% -$1.12M
LMNR icon
10
Limoneira
LMNR
$246M
$67K 0.5%
3,000
-3,200
-52% -$71.7K
BCPC
11
Balchem Corp
BCPC
$5.67B
$61K 0.46%
1,100
-16,400
-94% -$944K
OPWR
12
DELISTED
OPOWER INC COM STK (DE)
OPWR
$45K 0.34%
3,900
– –
DAR icon
13
Darling Ingredients
DAR
$9.69B
$40K 0.3%
2,700
-18,500
-87% -$273K
CVGW
14
DELISTED
Calavo Growers
CVGW
$31K 0.23%
600
-250
-29% -$13K
GMO
15
DELISTED
General Moly, Inc.
GMO
$11K 0.08%
+16,000
New +$11.4K
MSTR icon
16
Strategy Inc
MSTR
$54.6B
– –
-246,000
Closed -$4.16M
SANW
17
DELISTED
S&W Seed Co
SANW
– –
-4,505
Closed -$395K
SILC icon
18
Silicom
SILC
$274M
– –
-43,200
Closed -$1.78M
SMSI icon
19
Smith Micro Software
SMSI
$16.5M
– –
-2,653
Closed -$543K
TPST icon
20
Tempest Therapeutics
TPST
$17.9M
– –
-3
Closed -$323K
UI icon
21
Ubiquiti
UI
$35.9B
– –
-60,000
Closed -$1.77M
CSII
22
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-48,400
Closed -$1.89M
IPHI
23
DELISTED
INPHI CORPORATION
IPHI
– –
-68,300
Closed -$1.21M
ENT
24
DELISTED
Global Eagle Entertainment Inc.
ENT
– –
-3,896
Closed -$1.29M
CCC
25
DELISTED
Calgon Carbon Corp
CCC
– –
-13,700
Closed -$289K
1
2

Similar funds

SFM
Socratic Fund Management Short Hills, New Jersey $12M AUM 39.3% 1-Year Est. Return
IACGFA
IDG-Accel China Growth Fund Associates Central, Hong Kong $13.2M AUM 31.6% 1-Year Est. Return
LS
Lupo Securities Chicago, Illinois $13.3M AUM 1.59% 1-Year Est. Return
NGPI
N.G. Partners II Palo Alto, California $9.65M AUM 70.44% 1-Year Est. Return
AP
AGTC Partners Cambridge, Massachusetts $13.6M AUM 15.62% 1-Year Est. Return
GRP
Geologic Resource Partners Boston, Massachusetts $9.22M AUM 48.14% 1-Year Est. Return
NVPV
Norwest Venture Partners VIII Palo Alto, California $9.22M AUM
AC
Amiya Capital London, United Kingdom $14.3M AUM 4.61% 1-Year Est. Return

Sophrosyne Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Sophrosyne Capital held 35 positions worth $13.4M, down 77% from $58.3M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Sophrosyne Capital withdrew a net $45.1M in Q2 2015, closing 20 positions and reducing 13 holdings. Its most notable exit was ZELTIQ Aesthetics, Inc., an estimated $4.51M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 37% a quarter earlier, followed by Utilities and Communication Services.

Against the trend, Sophrosyne Capital opened a new position in General Moly, Inc. worth $11K.

  • Sophrosyne Capital's largest Q2 2015 buy was General Moly, Inc.: 16,000 shares worth $11K.
  • Sophrosyne Capital's biggest Q2 2015 reduction was iRadimed, cutting an estimated $4.94M.
  • Sophrosyne Capital fully exited ZELTIQ Aesthetics, Inc. in Q2 2015, selling an estimated $4.51M.
  • Sophrosyne Capital's ten largest holdings make up 99% of its $13.4M portfolio in Q2 2015.
  • Sophrosyne Capital opened 1 new position and closed 20 in Q2 2015.
  • Sophrosyne Capital's portfolio value fell 77% quarter-over-quarter to $13.4M.

Based on Sophrosyne Capital's 13F filing for Q2 2015, filed 14 Aug 2015.